
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is a strong buy for long-term investors, as evidenced by its consistently strong financial results and growing market share in the diabetes management space. While competition and potential market erosion pose risks, Insulet's innovative technology and expansion into new markets should continue to drive double-digit revenue growth over the intermediate term. With multiple key product launches on the horizon and a growing prescriber base, Insulet has solid fundamentals and a favorable valuation compared to its medtech peers.
Bears say
Insulet is facing increasing competition in the insulin infusion market as other companies develop similar products. While the Omnipod system has seen growth, PODD's late entry into the closed loop system for Type 2 diabetes patients puts it behind competitors who have already launched their own versions. Additionally, despite positive growth in international markets, PODD's high valuation and competitive landscape pose risks for investors.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares